Kringle Pharma,Inc. (4884.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.6x

Market Cap

JPY 2.97B

MomentumView details →

1D Return

−5.47%

YTD Return

+9.25%

RSI (14)

57.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.6x

Market Cap

JPY 2.97B

RSI (14)

57.1

MomentumView details →

1D Return

−5.47%

YTD Return

+9.25%

ProfitabilityView details →

Gross Margin

98.92%

Net Margin

−1260.27%

EBITDA Margin

—

ROE (TTM)

−97.15%

ROA (TTM)

−46.28%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+1.39%

EPS YoY

+4.28%

FCF YoY

—

Revenue CAGR 3Y

−43.11%

EPS CAGR 3Y

−13.29%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

4.79x

Quick Ratio

4.18x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

72.00M

Net Income (TTM)

−905.00M

Op. CF (TTM)

—

Next earningsNov 16, 2026 →

Latest newsMore news →

Kringle Pharma announced a joint research agreement with Yokohama City University to evaluate the efficacy of hepatocyte growth factor for chemotherapy-induced peripheral neuropathy.19h ago

Similar companies

SymBio Pharmaceuticals Limited4582.T Modalis Therapeutics Corporation4883.T Veritas In Silico Inc.130A.T MUROMACHI CHEMICALS INC.4885.T Medrx Co.,Ltd.4586.T Kubota Pharmaceutical Holdings Co.,Ltd.4596.T Find similar companies →

Latest newsMore news →

Kringle Pharma announced a joint research agreement with Yokohama City University to evaluate the efficacy of hepatocyte growth factor for chemotherapy-induced peripheral neuropathy.19h ago